Literature DB >> 8101846

Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells.

R Callaghan1, J R Riordan.   

Abstract

The ability of P-glycoprotein (P-gp) to transport naturally occurring and synthetic opiate analgesics was investigated. Multidrug-resistant Chinese hamster ovary cells (B30) were found to accumulate significantly lower amounts of morphine than their drug-sensitive counterparts (B1). This decreased accumulation was reversed upon depletion of cellular stores of ATP. In addition, morphine bound to plasma membranes from B30 cells in a specific, saturable fashion. Verapamil and vinblastine, compounds transported by P-gp, were able to increase accumulation and displace the binding of morphine in B30 cells. In turn, the synthetic opiates meperidine, pentazocine, and methadone were able to increase the accumulation of vinblastine in resistant cells. These compounds were also able to displace the specific binding of vinblastine and the photoaffinity labeling of P-gp in plasma membranes by the radioiodinated anthracycline, iodomycin. The implications of these findings in relation to the distribution, tolerance, and gastrointestinal side effects of opiates are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101846

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

2.  Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.

Authors:  Hazem E Hassan; Alan L Myers; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

Review 3.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

4.  Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.

Authors:  S P Letrent; G M Pollack; K R Brouwer; K L Brouwer
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 5.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 7.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

9.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

10.  In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Christophe Rousselle; Marcel Debray; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.